Researcher holding vaccine
Copyright 2021 The Associated Press. All rights reserved.
Currently, there are no standardized screening protocols available for ovarian cancer among women, which presents a significant challenge in early detection. While ovarian cancer is relatively rare—accounting for just 1% of the annual cancer diagnoses in the United States—its implications are severe. Studies indicate that approximately half of the nearly 20,000 women diagnosed with this disease annually survive for more than five years, a stark contrast to the over 90% survival rate for breast cancer over the same period.
Researchers from Cancer Research UK recently secured funding of £600,000 to pioneer the development of the first-ever ovarian cancer vaccine, known as OvarianVax. Dr. Matthew Block, a medical oncologist and immunologist affiliated with the Mayo Clinic, is focusing on utilizing engineered white blood cells harvested from patients already diagnosed with ovarian cancer for this groundbreaking vaccine. This innovative vaccine is designed to specifically target folate receptor alpha, a protein closely linked to the development of ovarian cancer.
Dr. Block elaborated on the divergence in aims between the projects, stating, “The vaccine developed at Mayo Clinic aims to support patients who are already contending with ovarian cancer. It is intended to prevent recurrence for those in remission and is also being investigated as part of the treatment regimen for active cases. Conversely, the UK’s vaccine is designed primarily for use in individuals at heightened risk for ovarian cancer who have never been diagnosed.”
Drawing parallels to existing cancer vaccines, Dr. Block noted that the well-known Gardasil 9 vaccine, which protects against several strains of the human papilloma virus (HPV), demonstrates effective cancer prevention through the elimination of long-term viral infections. He emphasized, “Unlike HPV, ovarian cancer is not thought to be caused by a viral agent. Thus, ovarian cancer vaccines focus on attacking specific proteins associated with tumor cells instead of viral proteins.” By targeting proteins expressed by cancer cells, the UK vaccine aims to lower overall cancer risks among individuals who have yet to receive a diagnosis.
Dr. Melissa Frey, a gynecologic oncologist and Director of the Genetics and Personalized Cancer Prevention Program at Weill Cornell Medicine, pointed out the absence of reliable screening options for ovarian cancer. For patients categorized as high-risk—such as those with BRCA1/2 mutations or Lynch syndrome—some healthcare professionals advocate for the use of transvaginal ultrasounds alongside CA-125 blood tests as potential screening tools.
While these methods could potentially enable earlier detection of ovarian cancer, Dr. Frey cautioned, “They are not included in the National Comprehensive Cancer Network’s guidelines for women predisposed to hereditary ovarian cancer. Furthermore, large-scale clinical trials have not demonstrated that these tests improve survival rates for those diagnosed with ovarian cancer.” She further indicated that while several groups are actively engaged in vaccine development, and clinical trials are underway, the timeline for an FDA-approved vaccine remains several years away.
What are the main goals of the OvarianVax vaccine developed by Dr. Matthew Block?
**Interview with Dr. Matthew Block on Ovarian Cancer Vaccine Development**
**Editor:** Thank you for joining us today, Dr. Block. You are at the forefront of a truly groundbreaking project with the development of OvarianVax. Can you tell us more about the significance of this vaccine?
**Dr. Block:** Absolutely. The development of OvarianVax is a monumental step in the fight against ovarian cancer. As you’ve mentioned, ovarian cancer is relatively rare but extremely deadly, with a stark difference in survival rates compared to other cancers like breast cancer. The goal of OvarianVax is to provide an additional layer of protection for women who are at high risk or have previously been treated for ovarian cancer.
**Editor:** You mentioned that the vaccine is engineered using white blood cells from patients already diagnosed with ovarian cancer. How does that process work?
**Dr. Block:** We collect white blood cells from patients who have undergone treatment and are currently in remission. These cells are then modified to better recognize and target folate receptor alpha, a protein that is closely associated with ovarian cancer cells. By enhancing the immune response to this specific target, the hope is to prevent cancer recurrence.
**Editor:** There’s another vaccine being developed in the UK. How does your project differ from that one?
**Dr. Block:** The UK vaccine is designed primarily for prevention in women who are at high risk of developing ovarian cancer, while our approach at the Mayo Clinic primarily focuses on supporting those who have already been diagnosed. It aims to prevent recurrences and assist those currently undergoing treatment. It’s essential to have both preventive and therapeutic strategies in place.
**Editor:** Given that there’s currently no standardized screening for ovarian cancer, how do you see the introduction of OvarianVax impacting early detection and treatment?
**Dr. Block:** While the vaccine itself is not a screening tool, it could complement existing strategies by potentially lowering the number of women who progress to late-stage ovarian cancer. If we can prevent recurrences or manage active cases more effectively, it may lead to improved survival rates and overall health for female patients.
**Editor:** Thank you, Dr. Block. This vaccine sounds like it could be a game changer in ovarian cancer treatment and prevention. We appreciate your insights and the valuable work you’re doing in this field.
**Dr. Block:** Thank you for having me. It’s crucial that we continue to push forward with research and support for those affected by this disease.
